nach oben

Cardiovascular Toxicology

Erschienen in:

01.06.2007

Anthracycline cardiotoxicity in long-term survivors of childhood cancer

verfasst von: Rebecca E. Scully, Steven E. Lipshultz

Erschienen in: Cardiovascular Toxicology | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Anthracycline chemotherapy is a widely-used and effective treatment for a wide spectrum of childhood cancers. Its use is limited by associated progressive and clinically significant cardiotoxic effects. Onset can be acute, early, or late. While acute onset is rare, long-term survivors have significantly elevated rates of cardiac morbidity and mortality. Major complications include cardiomyopathy, coronary artery disease, and atherosclerosis. Means of prevention and treatment continue to be explored including limiting cumulative anthracycline dose, controlling the rate of administration, and using liposomal preparations and novel anthracycline analogues. Dexrazoxane prior to anthracycline chemotherapy has been shown to significantly lower rates of elevated serum cardiac troponin levels, a marker of myocyte injury, indicating a cardioprotective effect. Pilot studies indicate that exercise interventions may also be beneficial in long-term survivors with cardiac damage. Support and study of this population to decrease the morbidity and morality associated with anthracycline-induced cardiotoxicity is indicated in a time sensitive fashion.

Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006). Cancer statistics, 2006. CA: A Cancer Journal for Clinicians, 56, 106–130.CrossRef

Oeffinger, K. C., Mertens, A. C., Sklar, C. A., Kawashima, T., Hudson, M. M., Meadows, A. T., Friedman, D. L., Marina, N., Hobbie, W., Kadan-Lottick, N. S., Schwartz, C. L., Leisenring, W., & Robison, L. L. (2006). Chronic health conditions in adult survivors of childhood cancer. The New England Journal of Medicine, 355, 1572–1582.PubMedCrossRef

Ries LA, Harkins D, Krapcho M, et al. (2006). SEER Cancer Statistics Review, 1975–2003, Bethesda, MD: National Cancer Institute.

Alvarez, J., Scully, R., Miller, T., Armstrong, F., Constine, L., Friedman, D., & Lipshultz, S. (2007). Long-term effects of treatments for childhood cancers. Current Opinion in Pediatrics, 19, 23–31.PubMedCrossRef

Lipshultz, S. E., & Sallan, S. E. (1993). Cardiovascular abnormalities in long-term survivors of childhood malignancy. Journal of Clinical Oncology, 11, 1199–1203.PubMed

Adams, M., Duffy, S., Constine, L., & Lipshultz, S. (2005). Cardiovascular effects of cancer therapy. In C. Schwartz, W. Hobbie, L. Constine & K. Ruccione (Eds.) Survivors of choldhood and adolescent cancer (pp. 133–159). Berlin-Heidelberg: Springer-Verlag.

Arceci, R. J. (2006). Surviving childhood cancer: a special series on the successes and challenges after “cure”. Pediatric Blood & Cancer, 46, 119–121.CrossRef

Bhatia, S., & Meadows, A. T. (2006). Long-term follow-up of childhood cancer survivors: future directions for clinical care and research. Pediatric Blood & Cancer, 46, 143–148.CrossRef

Oeffinger, K. C., & Hudson, M. M. (2004). Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA: A Cancer Journal for Clinicians, 54, 208–236.

10.

Moller, T. R., Garwicz, S., Barlow, L., Falck Winther, J., Glattre, E., Olafsdottir, G., Olsen, J. H., Perfekt, R., Ritvanen, A., Sankila, R., & Tulinius, H. (2001). Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. Journal of Clinical Oncology, 19, 3173–3181.PubMed

11.

Mertens, A. C., Yasui, Y., Neglia, J. P., Potter, J. D., Nesbit, M. E. Jr., Ruccione, K., Smithson, W. A., & Robison, L. L. (2001). Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. Journal of Clinical Oncology, 19, 3163–3172.PubMed

12.

Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Dalton, V. M., Mone, S. M., Gelber, R. D., & Colan, S. D. (2005). Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 23, 2629–2636.PubMedCrossRef

13.

Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991). Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. The New England Journal of Medicine, 324, 808–815.PubMedCrossRef

14.

Gewirtz, D. A. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical Pharmacology, 57, 727–741.PubMedCrossRef

15.

Doroshow, J. H., Locker, G. Y., & Myers, C. E. (1980). Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. The Journal of clinical investigation, 65, 128–135.PubMedCrossRef

16.

Lebrecht, D., Setzer, B., Ketelsen, U. P., Haberstroh, J., & Walker, U. A. (2003). Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation, 108, 2423–2429.PubMedCrossRef

17.

Wallace, K. B. (2003). Doxorubicin-induced cardiac mitochondrionopathy. Pharmacology & Toxicology, 93, 105–115.CrossRef

18.

Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56, 185–229.PubMedCrossRef

19.

Berry, G. J., & Jorden, M. (2005). Pathology of radiation and anthracycline cardiotoxicity. Pediatric blood & cancer, 44, 630–637.CrossRef

20.

Adams, M. J., & Lipshultz, S. E. (2005). Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatric Blood Cancer, 44, 600–606.PubMedCrossRef

21.

Giantris, A., Abdurrahman, L., Hinkle, A., Asselin, B., & Lipshultz, S. E. (1998). Anthracycline-induced cardiotoxicity in children and young adults. Critical Reviews in Oncology/Hematology, 27, 53–68.PubMedCrossRef

22.

Steinberg, J. S., Cohen, A. J., Wasserman, A. G., Cohen, P., & Ross, A. M. (1987). Acute arrhythmogenicity of doxorubicin administration. Cancer, 60, 1213–1218.PubMedCrossRef

23.

Frishman, W. H., Sung, H. M., Yee, H. C., Liu, L. L., Keefe, D., Einzig, A. I., & Dutcher, J. (1997). Cardiovascular toxicity with cancer chemotherapy. Current Problems in Cancer, 21, 301–360.PubMedCrossRef

24.

Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003). Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer, 97, 2869–2879.PubMedCrossRef

25.

Steinherz, L. J., Steinherz, P. G., Tan, C. T., Heller, G., & Murphy, M. L. (1991). Cardiac toxicity 4 to 20 years after completing anthracycline therapy. Jama, 266, 1672–1677.PubMedCrossRef

26.

Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995). Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. The New England Journal of Medicine, 332, 1738–1743.PubMedCrossRef

27.

Nysom, K., Holm, K., Lipsitz, S. R., Mone, S. M., Colan, S. D., Orav, E. J., Sallan, S. E., Olsen, J. H., Hertz, H., Jacobsen, J. R., & Lipshultz, S. E. (1998). Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 16, 545–550.PubMed

28.

Robert, J., Morvan, V. L., Smith, D., Pourquier, P., & Bonnet, J. (2005). Predicting drug response and toxicity based on gene polymorphisms. Critical Reviews in Oncology/Hematology, 54, 171–96.PubMedCrossRef

29.

Lipshultz, S. E., Lipsitz, S. R., Hinkle, A. S., Constine, L. S., French, C. A., Rovitelli, A. M. K., Proukou, C., Lopez-Mitnik, G., Adams, M. J., Hale, R., Rifai, N., & Miller, T. L. (2005). Cardiovascular status, subsequent risk, and associated factors in long-term survivors of childhood cancer in a population-based NCI study. Circulation 112, II-476 (#2292).

30.

Bhatia, R. S., Tu, J. V., Lee, D. S., Austin, P. C., Fang, J., Haouzi, A., Gong, Y., & Liu, P. P. (2006). Outcome of heart failure with preserved ejection fraction in a population-based study. The New England Journal of Medicine, 355, 260–9.PubMedCrossRef

31.

Owan, T. E., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006). Trends in prevalence and outcome of heart failure with preserved ejection fraction. The New England Journal of Medicine, 355, 251–9.PubMedCrossRef

32.

Wouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005). Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. British Journal of Haematology, 131, 561–78.PubMedCrossRef

33.

van Dalen, E. C., Caron, H. N., Dickinson, H. O. & Kremer, L. C. (2005). Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev, CD003917.

34.

Lipshultz, S. E., Giantris, A. L., Lipsitz, S. R., Kimball Dalton, V., Asselin, B. L., Barr, R. D., Clavell, L. A., Hurwitz, C. A., Moghrabi, A., Samson, Y., Schorin, M. A., Gelber, R. D., Sallan, S. E., & Colan, S. D. (2002). Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91–01 Acute Lymphoblastic Leukemia protocol. Journal of Clinical Oncology, 20, 1677–82.PubMedCrossRef

35.

Ewer, M. S., Martin, F. J., Henderson, C., Shapiro, C. L., Benjamin, R. S., & Gabizon, A. A. (2004). Cardiac safety of liposomal anthracyclines. Seminars in Oncology, 31, 161–81.PubMedCrossRef

36.

Theodoulou, M., & Hudis, C. (2004). Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer, 100, 2052–63.PubMedCrossRef

37.

Lahtinen, R., Kuikka, J., Nousiainen, T., Uusitupa, M., & Lansimies, E. (1991). Cardiotoxicity of epirubicin and doxorubicin: A double-blind randomized study. European Journal of Haematology, 46, 301–5.PubMedCrossRef

38.

Meinardi, M. T., van Veldhuisen, D. J., Gietema, J. A., Dolsma, W. V., Boomsma, F., van den Berg, M. P., Volkers, C., Haaksma, J., de Vries, E. G., Sleijfer, D. T., & van der Graaf, W. T. (2001). Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. Journal of Clinical Oncology, 19, 2746–53.PubMed

39.

Robert, J., Rigal-Huguet, F., & Hurteloup, P. (1992). Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. Hematological Oncology, 10, 111–6.PubMedCrossRef

40.

Martoni, A., Piana, E., Guaraldi, M., Cilenti, G., Farris, A., Saccani, F., Becchi, G., & Pannuti, F. (1990). Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer. Oncology, 47, 427–32.PubMedCrossRef

41.

Anderlini, P., Benjamin, R. S., Wong, F. C., Kantarjian, H. M., Andreeff, M., Kornblau, S. M., O’Brien, S., Mackay, B., Ewer, M. S., Pierce, S. A., et al. (1995). Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. Journal of Clinical Oncology, 13, 2827–34.PubMed

42.

Neidhart, J. A., Gochnour, D., Roach, R., Hoth, D., & Young, D. (1986). A comparison of mitoxantrone and doxorubicin in breast cancer. Journal of Clinical Oncology, 4, 672–7.PubMed

43.

Cowan, J. D., Neidhart, J., McClure, S., Coltman, C. A. Jr., Gumbart, C., Martino, S., Hutchins, L. F., Stephens, R. L., Vaughan, C. B., & Osborne, C. K. (1991). Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: A Southwest Oncology Group study. Journal of the National Cancer Institute, 83, 1077–84.PubMedCrossRef

44.

Herman, E. H., Zhang, J., Rifai, N., Lipshultz, S. E., Hasinoff, B. B., Chadwick, D. P., Knapton, A., Chai, J., & Ferrans, V. J. (2001). The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemotheraphy Pharmacology, 48, 297–304.CrossRef

45.

Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., Hurwitz, C. A., Moghrabi, A., Samson, Y., Schorin, M. A., Gelber, R. D., & Sallan, S. E. (2004). The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. The New England Journal of Medicine, 351, 145–153.PubMedCrossRef

46.

Sallan, S. E., & Lipshultz, S. E. (2005). Wise up: Do not do it without protection! Pediatric Blood & Cancer, 45, 872–873.CrossRef

47.

The SOLVD Investigators. (1991). Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The New England Journal of Medicine, 325, 293–302.

48.

The SOLVD Investigators. (1992). Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The New England Journal of Medicine, 327, 685–691.

49.

Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Simbre, V. C. 2nd, Shaikh, S. L., Mone, S. M., Gelber, R. D., & Colan, S. D. (2002). Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. Journal of Clinical Oncology, 20, 4517–4522.PubMedCrossRef

50.

Lipshultz, S. E., & Colan, S. D. (2004). Cardiovascular trials in long-term survivors of childhood cancer. Journal of Clinical Oncology, 22, 769–773.PubMedCrossRef

51.

Cardinale, D., Colombo, A., Sandri, M. T., Lamantia, G., Colombo, N., Civelli, M., Martinelli, G., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2006). Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation, 114, 2474–2481.PubMedCrossRef

52.

Lipshultz, S. E., Vlach, S. A., Lipsitz, S. R., Sallan, S. E., Schwartz, M. L., & Colan, S. D. (2005). Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics, 115, 1613–1622.PubMedCrossRef

53.

Cheitlin, M. D., Armstrong, W. F., Aurigemma, G. P., Beller, G. A., Bierman, F. Z., Davis, J. L., Douglas, P. S., Faxon, D. P., Gillam, L. D., Kimball, T. R., Kussmaul, W. G., Pearlman, A. S., Philbrick, J. T., Rakowski, H., Thys, D. M., Antman, E. M., Smith, S. C. Jr., Alpert, J. S., Gregoratos, G., Anderson, J. L., Hiratzka, L. F., Hunt, S. A., Fuster, V., Jacobs, A. K., Gibbons, R. J., & Russell, R. O. (2003). ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation, 108, 1146–1162.PubMedCrossRef

54.

Fried, I., Bar-Oz, B., Perles, Z., Rein, A. J., Zonis, Z., & Nir, A. (2006). N-terminal pro-B-type natriuretic peptide levels in acute versus chronic left ventricular dysfunction. The Journal of Pediatrics, 149, 28–31.PubMedCrossRef

55.

Bibbins-Domingo, K., Gupta, R., Na, B., Wu, A. H., Schiller, N. B., & Whooley, M. A. (2007). N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. Jama, 297, 169–176.PubMedCrossRef

56.

Miller, T. L., Horgan, S., & Lipshultz, S. E. (2005). Exercise rehabilitation of pediatric patients with cardiovascular disease. Progress in Pediatric Cardiology, 20, 27–37.CrossRef

57.

Hinkle, A. S., Proukou, C., French, C. A., Kozlowski, A. M., Constine, L. S., Lipsitz, S. R., Miller, T. L., & Lipshultz, S. E. (2004). A clinic-based, comprehensive care model for studying late effects in long-term survivors of pediatric illnesses. Pediatrics, 113, 1141–1145.PubMed

58.

Grenier, M. A., & Lipshultz, S. E. (1998). Epidemiology of anthracycline cardiotoxicity in children and adults. Seminars in Oncology, 25, 72–85.PubMed

Titel: Anthracycline cardiotoxicity in long-term survivors of childhood cancer
verfasst von: Rebecca E. Scully
Steven E. Lipshultz
Publikationsdatum: 01.06.2007
Verlag: Humana Press Inc
Erschienen in: Cardiovascular Toxicology / Ausgabe 2/2007
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-007-0006-4

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2007

Long-term and short-term models for studying anthracycline cardiotoxicity and protectors

Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis

Pathophysiology and diagnosis of cancer drug induced cardiomyopathy

Role of mtDNA lesions in anthracycline cardiotoxicity

Molecular and cellular mechanisms of anthracycline cardiotoxicity

Other uses of dexrazoxane: savene, the first proven antidote against anthracycline extravasation injuries